Insider Trading March 17, 2026

Alphatec COO Disposes $3.2 Million in Shares as Analysts Reprice Targets

Lish Scott's March sale, recent Q4 beats and a board retirement add nuance to Alphatec's valuation debate

By Jordan Park ATEC
Alphatec COO Disposes $3.2 Million in Shares as Analysts Reprice Targets
ATEC

Alphatec Holdings COO Lish Scott sold 260,535 shares on March 13, 2026, netting $3,204,580. The transaction, disclosed in a Form 4 filing, leaves Scott with 815,704 shares. The stock trades at $13.05, down 38% year-to-date despite 25% revenue growth over the prior 12 months. Analysts have reacted to mixed signals from results and revenue guidance, adjusting price targets while maintaining generally constructive ratings.

Key Points

  • COO Lish Scott sold 260,535 shares on March 13, 2026, for $3,204,580; she retains 815,704 shares - impacts corporate insider activity and market perception.
  • Alphatec reported Q4 EBITDA that beat firm and Street estimates by $2 million even as some analysts trimmed price targets due to a weaker Q1 2026 revenue outlook - relevant to equity analysts and healthcare investors.
  • InvestingPro flagged ATEC as overvalued relative to Fair Value while noting analysts expect profitability this year, reflecting valuation debate in the healthcare/medtech sector.

Summary

Alphatec Holdings' (NASDAQ: ATEC) chief operating officer, Lish Scott, completed a sale of 260,535 common shares on March 13, 2026, generating proceeds of $3,204,580. Prices on individual lots from the trade ranged between $12.20 and $12.42. Following the sale, Scott holds 815,704 shares directly, according to a Form 4 filing with the Securities and Exchange Commission.


Insider transaction details

The Form 4 disclosure records the March 13 disposition of 260,535 shares by the company's COO for total consideration of $3,204,580, with executed prices spanning $12.20 to $12.42 per share. The filing documents Scott's remaining direct ownership at 815,704 shares of Alphatec common stock.


Market context and valuation signals

Alphatec's shares are quoted at $13.05 and have declined 38% year-to-date even though the company reported 25% revenue growth over the last twelve months. An InvestingPro analysis included in public reporting classifies the stock as overvalued relative to its Fair Value and places it on a Most Overvalued list. That same InvestingPro note also records that analysts expect the company to reach profitability this year and references a Pro Research Report covering ATEC among more than 1,400 U.S. equities.


Earnings, analyst responses and guidance concerns

Alphatec's fourth-quarter results were consistent with earlier indications, with adjusted EBITDA exceeding both firm and consensus Street estimates by $2 million. Despite the upside in EBITDA, several brokerages have adjusted their positioning on the stock in light of a softer near-term revenue outlook.

Stifel lowered its price target from $24 to $20 but kept a Buy rating, citing concerns around a weaker revenue outlook for the first quarter of 2026. Piper Sandler reaffirmed an Overweight rating and a $25 price target, noting that fourth-quarter revenue and earnings surpassed their projections. Freedom Capital Markets maintained a Buy rating with a $25 price target and described Alphatec's full-year 2025 results as largely uneventful but in line with expectations. Lake Street Capital Markets continues to carry a Buy rating and a $25 target, pointing to strong growth in the spine market as a positive.


Corporate governance update

Director Ward W. Woods announced his retirement effective February 27, 2026, reducing Alphatec's board to seven members. The company reported that Woods' departure was not the result of any disagreement with Alphatec, and that he has entered into a Vesting Acceleration Agreement covering his unvested stock units.


Takeaway

Collectively, these items - an insider sale, mixed analyst revisions, strong EBITDA performance and a director retirement - present a combination of positive operating outcomes and strategic adjustments within Alphatec. The company's recent results and the varied analyst responses highlight the tension between near-term revenue concerns and longer-term growth drivers in the spine market.

Risks

  • Near-term revenue weakness - Stifel cited concerns about a softer revenue outlook for Q1 2026, which could affect near-term earnings expectations and investor sentiment in the healthcare and medtech sectors.
  • Valuation disconnect - InvestingPro places ATEC on a Most Overvalued list despite recent revenue growth, posing a valuation risk for equity investors.
  • Board change uncertainty - The retirement of director Ward W. Woods reduces the board to seven members and, while not due to disagreement, introduces governance and succession considerations for stakeholders.

More from Insider Trading

Navitas CFO Sells $1.06M of NVTS Stock Amid Transition and Product Announcements Mar 17, 2026 Astera Labs Director Disposes $325,000 in Stock as Company Posts Strong Q4 Results Mar 17, 2026 GeneDx CEO Sells $1.32M in WGS Stock to Meet RSU Tax Withholding Mar 17, 2026 PACS Group COO Sells $1.24M in Shares as Stock Trades Well Above Analyst Targets Mar 17, 2026 GeneDx CFO Disposes $438K in Stock Following Zero-Strike Option Exercise Mar 17, 2026